Johnson & Johnson (NYSE:JNJ) is reportedly shuttering its cardiovascular and metabolic drug unit as part of a restructuring of its pharmaceutical division.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,